Literature DB >> 16740694

D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness.

Yaqin Zhang1, Baolin Zhang.   

Abstract

D4-GDI is a Rho GDP dissociation inhibitor that is widely expressed in hematopoietic cells. Its possible expression and function in breast cancer cells has not been described. Here, we found that D4-GDI is expressed in a panel of breast cancer cell lines, but not in benign-derived mammary epithelial cells. Knockdown of D4-GDI expression in MDA-MB-231 cells by RNA interference blocks cell motility and invasion. The cells lacking D4-GDI grown on Matrigel revert to a normal breast epithelial phenotype characterized by the formation of cavitary structures. Silencing D4-GDI expression inhibits beta1-integrin expression and cell-matrix adhesion. Reintroduction of D4-GDI fully restored both beta1-integrin expression and cellular invasion. Knockdown of D4-GDI in BT549 cells results in a similar effect. These results show that D4-GDI modulates breast cancer cell invasive activities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740694     DOI: 10.1158/0008-5472.CAN-05-4004

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

Review 2.  Perineural invasion and associated pain in pancreatic cancer.

Authors:  Aditi A Bapat; Galen Hostetter; Daniel D Von Hoff; Haiyong Han
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 3.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

4.  Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling.

Authors:  Yaqin Zhang; Leslie A Rivera Rosado; Sun Young Moon; Baolin Zhang
Journal:  J Biol Chem       Date:  2009-03-06       Impact factor: 5.157

5.  Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach.

Authors:  Anh T P Ngo; Marisa L D Thierheimer; Özgün Babur; Anne D Rocheleau; Tao Huang; Jiaqing Pang; Rachel A Rigg; Annachiara Mitrugno; Dan Theodorescu; Julja Burchard; Xiaolin Nan; Emek Demir; Owen J T McCarty; Joseph E Aslan
Journal:  Am J Physiol Cell Physiol       Date:  2017-02-01       Impact factor: 4.249

6.  RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer.

Authors:  Sung Ae Koh; Min Kyoung Kim; Kyung Hee Lee; Sang Woon Kim; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2014-09-25       Impact factor: 5.150

7.  Sublethal concentrations of the platinum(II) complex [Pt(O,O'-acac)(gamma-acac)(DMS)] alter the motility and induce anoikis in MCF-7 cells.

Authors:  Antonella Muscella; Nadia Calabriso; Carla Vetrugno; Loredana Urso; Francesco Paolo Fanizzi; Sandra Angelica De Pascali; Santo Marsigliante
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

8.  Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective.

Authors:  Amber Ilyas; Zehra Hashim; Shamshad Zarina
Journal:  Mol Cell Biochem       Date:  2015-04-09       Impact factor: 3.396

9.  Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation.

Authors:  Ming-Chun Lai; Qian-Qian Zhu; Kwabena-Gyabaah Owusu-Ansah; Yang-Bo Zhu; Zhe Yang; Hai-Yang Xie; Lin Zhou; Li-Ming Wu; Shu-Sen Zheng
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

10.  RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells.

Authors:  Zhong Zheng; Xiang-Yi He; Jian-Fang Li; Bei-Qin Yu; Xue-Hua Chen; Jun Ji; Jia-Nian Zhang; Qin-Long Gu; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  Oncol Lett       Date:  2012-10-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.